Phase 1/2 Study to Evaluate Palbociclib (Ibrance?) in Combination with Irinotecan and Temozolomide or in Combination with Topotecan and Cyclophosphamide in Pediatric Patients with Recurrent or Refractory Solid Tumors
Objective
Primary Objective(s):To estimate the MTD for the combination of palbociclib, TMZ, and IRN in children, adolescents, and young adults with recurrent or refractory solid tumors.